Clinical Trials Search
Title |
Intervention | NCT ID | Sponsor |
|---|---|---|---|
| Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer | Aspirin, Eflornithine, Laboratory Biomarker Analysis, Placebo, Telephone-Based Intervention | NCT00983580 | National Cancer Institute (NCI) |
| Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung Nodules | Aspirin, Laboratory Biomarker Analysis, Placebo | NCT02169271 | National Cancer Institute (NCI) |
| Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy | Real Acupressure Band, Placebo Acupressure Band | NCT01346267 | University of South Florida |
| Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer | Acupuncture | NCT01141231 | M.D. Anderson Cancer Center |
| Adaptation of Individual Meaning-Centered Psychotherapy for Chinese Immigrant Cancer Patients | In-depth Patient Interviews, Adaptation of IMCP for Chinese Immigrant Cancer Patients | NCT02112188 | Memorial Sloan Kettering Cancer Center |
| Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and... | Olanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant), Placebo | NCT02116530 | Alliance for Clinical Trials in Oncology |
| Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma | armodafinil 150 mg, Placebo, armodafinil 250 mg | NCT01781468 | Alliance for Clinical Trials in Oncology |
| Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers | Aspirin, Laboratory Biomarker Analysis, Placebo, Zileuton | NCT02348203 | National Cancer Institute (NCI) |
| Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful... | Aspirin, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration | NCT02521285 | National Cancer Institute (NCI) |
| Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic... | behavioral intervention, mercaptopurine, standard follow-up care, compliance monitoring, questionnaire administration, laboratory biomarker analysis | NCT01503632 | Children's Oncology Group |